DisclosedRx

DISCLOSEDRX / CASE STUDY



A more controlled approach to pharmacy spend.

The problem: unsustainable pharmacy cost trend.

An industry-leading provider of construction and maintenance services faced a rapidly escalating pharmacy benefit challenge driven by high-cost specialty therapies and GLP-1 medications.


THE BASELINE

$107.95	237	$21,806	$1,647,811
2024 pharmacy PMPM	Ozempic + Mounjaro fills	Average gross cost per Skyrizi fill	Year 1 gross pharmacy cost*

*Reported gross pharmacy cost before documented Savings Program savings.

The solution: a controlled savings approach.

The company implemented a DisclosedRx-managed pharmacy benefit as part of a broader benefits redesign, pairing clinical oversight with a fill-level Savings Program. For prescriptions with significant cost exposure, a Savings Advocate reviewed available options and helped members pursue the appropriate savings pathway.



PLAN SAVINGS BY CHANNEL

- Alternative sourcing · **$259K**
- Copay cards & coupons · **$56K**
- Patient assistance · **<$1K**

01

ALTERNATIVE SOURCING $259K

Eligible medications were sourced through licensed international channels and 340B pharmacies at a much lower cost, often with zero copay or deductible.

02

COPAY CARDS & COUPONS $56K

Eligible manufacturer copay programs were applied at the prescription level to reduce costs at the point of sale.

03

PATIENT ASSISTANCE <$1K


For members who met program criteria, Advocates pursued manufacturer patient-assistance programs.

Savings pathways were selected based on prescription eligibility and the member's circumstances. Amounts shown by pathway are documented plan savings, rounded for presentation.

The outcome: immediate financial relief.

$327,586

The targeted review of 482 high-cost prescription fills transformed the financial trajectory of the company's pharmacy plan. DisclosedRx documented $327,586 in total pharmacy savings across 482 prescription fills in Year 1.



DOCUMENTED SAVINGS DISTRIBUTION

Plan **$316,071** Member **$11,515**


WHERE THE SAVINGS CAME FROM

MEDICATION	FILLS	GROSS COST	DOCUMENTED PLAN SAVINGS
Skyrizi	9	$196,256	**$63,244**
Tremfya	10	$142,810	**$61,764**
Jardiance	49	$62,841	**$31,879**
Ozempic	116	$179,173	**$28,709**
Mounjaro	121	$160,861	**$15,765**

Selected medications with the highest documented plan savings, Year 1.

Pharmacy PMPM plummeted 42%.

During Year 1 of the DisclosedRx-managed pharmacy benefit, the company's pharmacy PMPM declined from $107.95 to $62.54. This result reflects the combined effect of the Savings Program, an 87% generic fill rate, managed GLP-1 utilization, plan design, and member utilization during the period. It should not be interpreted as Savings Program impact alone.



WHAT THE CLIENT RECEIVED

- **NDC-11 level reporting**
- **A structured review process**
- **Savings directed to plan and members**
- **A cost-management and member-support model**

Learn how DisclosedRx can increase your organization's savings while maintaining excellent member care.

Call 1-480-561-6005 · **Email sales@disclosedrx.com**

Savings reflect DisclosedRx-reported, fill-level documented savings during Year 1. Pharmacy PMPM reflects the client's reported experience for the stated periods and can